NKTR Nektar Therapeutics

Price (delayed)

$16.99

Market cap

$3.05B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.49

Enterprise value

$3.15B

Sector: Healthcare
Industry: Biotechnology

Highlights

The debt has shrunk by 62% YoY
The gross profit has increased by 45% year-on-year
Nektar Therapeutics's quick ratio has decreased by 36% YoY and by 10% from the previous quarter
Nektar Therapeutics's equity has decreased by 21% YoY and by 7% QoQ

Key stats

What are the main financial stats of NKTR
Market
Shares outstanding
179.4M
Market cap
$3.05B
Enterprise value
$3.15B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.6
Price to sales (P/S)
18.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.27
Earnings
Revenue
$163.32M
EBIT
-$426.48M
EBITDA
-$411.97M
Free cash flow
-$349.05M
Per share
EPS
-$2.49
Free cash flow per share
-$1.95
Book value per share
$6.55
Revenue per share
$0.91
TBVPS
$8
Balance sheet
Total assets
$1.51B
Total liabilities
$337.69M
Debt
$154.37M
Equity
$1.17B
Working capital
$917.36M
Liquidity
Debt to equity
0.13
Current ratio
8.25
Quick ratio
7.9
Net debt/EBITDA
-0.24
Margins
EBITDA margin
-252.3%
Gross margin
87.1%
Net margin
-269.8%
Operating margin
-259.6%
Efficiency
Return on assets
-25.3%
Return on equity
-34.4%
Return on invested capital
-26.8%
Return on capital employed
-30.9%
Return on sales
-261.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NKTR stock price

How has the Nektar Therapeutics stock price performed over time
Intraday
-4.55%
1 week
-11.56%
1 month
-7.81%
1 year
-27.67%
YTD
-0.06%
QTD
-0.06%

Financial performance

How have Nektar Therapeutics's revenue and profit performed over time
Revenue
$163.32M
Gross profit
$142.17M
Operating income
-$424.03M
Net income
-$440.68M
Gross margin
87.1%
Net margin
-269.8%
The gross profit has increased by 45% year-on-year
The revenue has grown by 35% YoY
The operating margin has grown by 27% YoY
The net margin has increased by 24% YoY

Growth

What is Nektar Therapeutics's growth rate over time

Valuation

What is Nektar Therapeutics stock price valuation
P/E
N/A
P/B
2.6
P/S
18.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.27
Nektar Therapeutics's EPS has decreased by 2% QoQ
The P/B is 97% below the 5-year quarterly average of 92.3 and 3.7% below the last 4 quarters average of 2.7
Nektar Therapeutics's equity has decreased by 21% YoY and by 7% QoQ
The revenue has grown by 35% YoY
The stock's P/S is 25% less than its last 4 quarters average of 24.9 and 11% less than its 5-year quarterly average of 20.9

Efficiency

How efficient is Nektar Therapeutics business performance
The return on invested capital has declined by 43% year-on-year and by 17% since the previous quarter
Nektar Therapeutics's ROE has decreased by 29% YoY and by 9% from the previous quarter
NKTR's ROA is down by 26% YoY and by 11% from the previous quarter
Nektar Therapeutics's return on sales has increased by 23% YoY but it has decreased by 3.2% QoQ

Dividends

What is NKTR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NKTR.

Financial health

How did Nektar Therapeutics financials performed over time
Nektar Therapeutics's quick ratio has decreased by 36% YoY and by 10% from the previous quarter
The company's current ratio fell by 35% YoY and by 11% QoQ
The debt is 87% lower than the equity
The debt to equity has shrunk by 52% YoY but it rose by 8% QoQ
Nektar Therapeutics's equity has decreased by 21% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.